FDA Inspection
Adarsh Daswani, M.D.Adarsh Daswani, M.D. – FDA Inspection, Oct 29, 2021
Record Details
This FDA Inspection record concerns Adarsh Daswani, M.D., with an inspection on October 29, 2021, issued by the Center for Drug Evaluation and Research, covering drugs.
- Company
- Adarsh Daswani, M.D.
- Inspection Date
- October 29, 2021
- Product Type
- Drugs
View Company Profile
ID · a06db396-f0f3-4af9-baf5-89acf2da6e67
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1155496
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring
- Enforcement
- Warning Letter
FDA Citations
3- 21 CFR 312.60FD-1572, protocol compliance
- 21 CFR 312.62(b)Case history records- inadequate or inadequate
- 21 CFR 312.62(a)Accountability records
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Adarsh Daswani, M.D.
1| Date | Classification | Office | Project area |
|---|---|---|---|
| February 7, 2025 | Not classified | Los Angeles District Office | Bioresearch Monitoring: Human Drugs |
Other documents for Adarsh Daswani, M.D.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.